Verve Therapeutics (NASDAQ: VERV)
Some price data may be temporarily unavailable.
Verve Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Verve Therapeutics Company Info
Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan, Burt A. Adelman, and Barry Ticho in 2018 and is headquartered in Boston, MA.
News & Analysis
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
Top ETFs Tracking CRISPR Gene Editing
These exchange-traded funds track companies in this biotech space.
Why Verve Therapeutics Stock Is Skyrocketing Today
Why Verve Therapeutics Is Skyrocketing Today
After a Serious Setback, Is Verve Therapeutics a Buy?
There are a few silver linings at play here.
Why Verve Therapeutics Stock Crashed as Much as 30% This Week
There was a concerning development in the company's clinical trials.
Verve Therapeutics: Why Great Results Aren't Enough
The company's twist on CRISPR appears to work as intended but that didn't stop this biotech's stock price from collapsing.
After Its Stock Crashed 42% in 1 Day, Is Verve Therapeutics a Buy?
It reported some very bad news, but the market might be overreacting.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.